Immunopathology of SARS-CoV-2 and analysis of immunizers in brazilian territory
Keywords:
COVID-19; SARS-CoV-2; Pharmacists; Vaccines.Abstract
SARS-COV-2 belongs to the family Coronaviridae and is responsible for the disease called COVID-19, considered a global public health problem. The present study aimed to describe the immunopathology of COVID-19 and the vaccines currently available. This is a descriptive analysis study with a qualitative approach, on the immunopathology of COVID-19 and the vaccines currently available. In Brazil, the National Health Surveillance Agency approved on an emergency basis on January 17, 2021, the CoronaVac immunizers from the Chinese laboratory SINOVAC in partnership with the Butantan Institute, located in the state of São Paulo, and the AstraZeneca from the University of Oxford in England in partnership with Fiocruz in Rio de Janeiro. It should be noted that they still have other vaccines developed that are awaiting emergency approval by ANVISA. However, in the current context, those with storage at 2 to 8ºC become viable in the Brazilian climate, commonly for immunizers of other diseases without the need for deep freezers. It is concluded that vaccines are guarantees of immunological efficacy to protect the population against the disease.
Downloads
References
APS, L. R. M. M. et al. Eventos adversos de vacinas e as consequências da não vacinação: uma análise crítica. Rev. Saúde. Pública, v. 52, n. 40, p. 1-13, 2018.
BADEN, L. R. et al. Efficacy and safety of the mRNA-1273 SARV-CoV-2 vaccine. The New England Journal of Medicine, v. 384, n. 5, p. 403-416, 2021.
BRASIL. Saúde confirma caso de reinfecção por nova cepa da Covid-19. 2021. Acesso em: 17 de janeiro de 2021. Disponível em: <https://www.gov.br/saude/pt-br/assuntos/noticias/saude-confirma-caso-de-reinfeccao-por-nova-cepa-da-covid-19>
CAPONI, S. Covid-19 no Brasil: entre o negacionismo e a razão neoliberal. Estudos avançados, v. 34, n. 99, p. 209-223, 2020.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). US COVID-19 Cases Caused by Variants. 2021. Acesso em: 17 de janeiro de 2021. Disponível em: <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html>
CHEN, Y. et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Research Reviews, v. 65, p. 1-11, 2021.
DEJNIRATTISAI, W; ZHOU, D; SUPASA, P; LIU, C; MENTZER, A.J; GINN, H. M. Antibody evasion by the Brazilian P.1 strain of SARS -CoV-2. bioRxiv. 2021. Disponível em: <https://www.biorxiv.org/content/10.1101/2021.03.12.435194v1.full.pdf>
EUSER, S. et al. SARS-CoV-2 viral load distribution in different patient populations and age groups reveals that viral loads increase with age. medRxiv, p. 1-20, 2021.
FERRARI, F. COVID-19: Dados Atualizados e sua Relação Com o Sistema Cardiovascular. Arq. Bras. Cardiol., v. 114, n. 5, p.823-826, 2020.
GAEBLER, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature, p. 1-33, 2021.
INSTITUTO BUTANTAN. CoronaVac. 2020. Disponível em: <https://vacinacovid.butantan.gov.br/bulas>
KNOLL, M. D.; WONODI, C. Oxford-AstraZeneca COVID-19-vaccine efficacy. The Lancet. v. 397, p. 72-74, 2021.
LOAYZA-ALARICO, M. J.; CRUZ-VARGAS, J. A. D. L. Efecto de las variantes de SARS-CoV-2 en la transmisión de COVID-19 en el Perú. Rev. Fac. Med. Hum., v. 21, n. 1, p. 10-11, 2021.
NASCIMENTO, C. B. C. et al. SARS-CoV2 e Covid-19: aspectos fisiopatológicos e imunológicos, estratégias de diagnóstico e desenvolvimento de vacinas. Revista
Interdisciplinar de Saúde e Educação Ribeirão Preto, v. 1, n. 2, p. 122-158, 2020.
ORGANIZAÇÃO MUNDIAL DE SAÚDE (OMS). 2020. Disponível em: <https://www.who.int/eportuguese/countries/bra/pt/>
Organização Pan-Americana da Saúde (OPAS). Atualização epidemiológica: Ocorrência de variantes de SARS-CoV-2 nas Américas. 2021. Disponível em: <https://www.paho.org/pt/file/80853/download?token=FPTfm0D>
PACES, J. et al. COVID-19 and the Immune System. Physiol. Res., v. 69, p. 379-388, 2020.
PLATTO, S.; XUE, T.; CARAFOLI, E. COVID19: an announced pandemic. Cell Death Dis, v. 11, n. 799, p. 1-13, 2020.
POLACK, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine, v. 383, n. 27, p. 2603-2615, 2020.
SANTOS, W. G. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomedicine & Pharmacoterapy, v. 136, p. 1-15, 2021.
SILVEIRA, F. S. et al. Peculiaridades da infecção por Sars-CoV-2 em pediatria. Braz. J. of Develop., v.6, n. 12, p.101575-10158, 2020.
SINOVAC. Summary of Clinical Trial Data of Sinovac’s COVID-19 Vaccine. 2021. Disponível em: <http://www.sinovac.com/?optionid=754&auto_id=927>
TAY, M. Z. et al. The trinity of COVID-19: immunity, inflammation and interventioN. Nature Reviews Immunology, v. 20, p. 363-374, 2020.
VELAVAN, T. P.; MEYER, C. G. The COVID?19 epidemic. Trop Med Int Health, v. 25, n. 3, p. 278-280, 2020.
WIERSINGA, W. J. et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). JAMA, v. 324, n. 8, p. 782-793, 2020.
ZHENG, S. et al. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res Social Adm Pharm., v. 17, n. 1, p. 1819-1824, 2021.
Português (Brasil)
English
Español (España)